MX2007012656A - Seleccion y uso de bacterias acido lacticas para reducir la inflamacion en mamiferos. - Google Patents

Seleccion y uso de bacterias acido lacticas para reducir la inflamacion en mamiferos.

Info

Publication number
MX2007012656A
MX2007012656A MX2007012656A MX2007012656A MX2007012656A MX 2007012656 A MX2007012656 A MX 2007012656A MX 2007012656 A MX2007012656 A MX 2007012656A MX 2007012656 A MX2007012656 A MX 2007012656A MX 2007012656 A MX2007012656 A MX 2007012656A
Authority
MX
Mexico
Prior art keywords
cells
strains
tnfa
inflammation
conditioned medium
Prior art date
Application number
MX2007012656A
Other languages
English (en)
Spanish (es)
Inventor
Eamonn Connolly
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of MX2007012656A publication Critical patent/MX2007012656A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2007012656A 2005-04-15 2006-04-12 Seleccion y uso de bacterias acido lacticas para reducir la inflamacion en mamiferos. MX2007012656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/107,438 US7344867B2 (en) 2005-04-15 2005-04-15 Selection and use of lactic acid bacteria for reducing inflammation in mammals
PCT/SE2006/000434 WO2006110088A1 (en) 2005-04-15 2006-04-12 Selection and use of lactic acid bacteria for reducing inflammation in mammals

Publications (1)

Publication Number Publication Date
MX2007012656A true MX2007012656A (es) 2007-12-13

Family

ID=37087291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012656A MX2007012656A (es) 2005-04-15 2006-04-12 Seleccion y uso de bacterias acido lacticas para reducir la inflamacion en mamiferos.

Country Status (16)

Country Link
US (2) US7344867B2 (enExample)
EP (1) EP1868622B1 (enExample)
JP (1) JP4740999B2 (enExample)
KR (1) KR101042123B1 (enExample)
CN (1) CN101160134B (enExample)
AU (1) AU2006234793B2 (enExample)
DK (1) DK1868622T3 (enExample)
ES (1) ES2606765T3 (enExample)
HU (1) HUE032297T2 (enExample)
LT (1) LT1868622T (enExample)
MX (1) MX2007012656A (enExample)
PL (1) PL1868622T3 (enExample)
PT (1) PT1868622T (enExample)
RU (1) RU2378370C2 (enExample)
SI (1) SI1868622T1 (enExample)
WO (1) WO2006110088A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
US20110293710A1 (en) * 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
US8785183B2 (en) * 2010-09-21 2014-07-22 Biogaia Ab Active plastic material in oil
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
ES2402014B1 (es) 2011-09-07 2014-02-27 Consejo Superior De Investigaciones Científicas (Csic) Peptido secretado por lactobacillus plantarum con función inmunomoduladora
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
HUE042643T2 (hu) 2012-06-04 2019-07-29 Biogaia Ab Lactobacillus reuteri ATCC PTA 6475 csontveszteség
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ES2874479T3 (es) * 2014-01-23 2021-11-05 Biogaia Ab Agentes que modulan el dolor gastrointestinal
JP2018510631A (ja) * 2015-03-26 2018-04-19 バイオガイア・エイビーＢｉｏｇａｉａ ＡＢ ヒスタミン産生細菌株及びがんにおけるそれらの使用
US10376563B1 (en) 2016-02-12 2019-08-13 Wisconsin Alumni Research Foundation Methods for systemically delivering polypeptides and microorganisms therefor
HUE062788T2 (hu) 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
EP3897836B1 (en) 2019-11-08 2023-08-16 Biogaia AB Serotonin producing bacteria
CN114196581B (zh) * 2020-12-16 2023-06-13 江南大学 缓解高尿酸血症的罗伊氏乳杆菌ccfm1132及应用
WO2023007468A1 (en) 2021-07-30 2023-02-02 Helaina, Inc. Methods and compositions for protein synthesis and secretion
JPWO2023063314A1 (enExample) 2021-10-11 2023-04-20
KR102752058B1 (ko) * 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) * 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) * 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
AU5773600A (en) * 1999-06-30 2001-01-31 Board Of Regents Of The University Of Nebraska, The Method of isolation of regulated virulence determinants from bacterial pathogens
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Also Published As

Publication number Publication date
RU2007142174A (ru) 2009-05-20
KR101042123B1 (ko) 2011-06-16
US7344867B2 (en) 2008-03-18
HK1115730A1 (en) 2008-12-05
KR20070121700A (ko) 2007-12-27
WO2006110088A1 (en) 2006-10-19
EP1868622A4 (en) 2011-11-02
ES2606765T3 (es) 2017-03-27
LT1868622T (lt) 2017-01-10
US20060233775A1 (en) 2006-10-19
DK1868622T3 (en) 2017-01-16
CN101160134B (zh) 2012-08-22
EP1868622A1 (en) 2007-12-26
CN101160134A (zh) 2008-04-09
PL1868622T3 (pl) 2017-04-28
US20080107635A1 (en) 2008-05-08
JP4740999B2 (ja) 2011-08-03
SI1868622T1 (sl) 2017-01-31
PT1868622T (pt) 2016-12-29
AU2006234793A1 (en) 2006-10-19
JP2008538288A (ja) 2008-10-23
EP1868622B1 (en) 2016-09-28
RU2378370C2 (ru) 2010-01-10
HUE032297T2 (en) 2017-09-28
AU2006234793B2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
US20080107635A1 (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
Zhang et al. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-α–induced interleukin-8 production in caco-2 cells
US7678553B2 (en) Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
Guarner et al. Role of bacteria in experimental colitis
CN101171019B (zh) 免疫功能调节剂
Paturi et al. Immune enhancing effects of Lactobacillus acidophilus LAFTI L10 and Lactobacillus paracasei LAFTI L26 in mice
SK71293A3 (en) Biologic pure bacterial culture of lactic fermentation
EP2220210A1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
KR101277050B1 (ko) 조제유-수유 영아에서 전신 염증을 치료, 예방 또는감소하기 위한, 장쇄 다중불포화 지방산과 병용되는락토바실러스 람노수스 ｇｇ의 용도
CN105132328A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum strain suo及其用途
CN105154362A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum suo及其保健用途
Karlsson et al. Lactobacilli differently regulate expression and secretion of CXCL8 in urothelial cells
HK1115730B (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
KR100887822B1 (ko) 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역기능을 향상시키는 방법
KR100887819B1 (ko) 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역 기능을 향상시키는 방법
McCoy Effects of feeding Lactobacillus reuteri X-18 on blood chemistry and immune parameters in beagle (Canis familiaris) puppies
Gnauck The impact of probiotic bacteria on gene expression of Interleukin-8, Interleukin-17 and CASP3 in Caco-2 cells

Legal Events

Date Code Title Description
FG Grant or registration